Algeta ASA raised €23 million (US$28.8 million) in a Series A funding to continue development of its lead product, Alpharadin, a cancer therapeutic based on radium-223 (Ra-223), which is undergoing Phase II studies in skeletal metastases arising from prostate cancer. (BioWorld International) Read More
